Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.51 |
| ▸ | TRPV6 | Q9H1D0 | 5/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7333163 | 0.85 | KDM4E (0.55) | KDM4EALDH1A1MEN1KMT2AITGB3 | |
| SCHEMBL6134717 | 0.83 | ITGB3 (0.52) | KDM4EALDH1A1MEN1KMT2AITGB3 | |
| SCHEMBL6132215 | 0.83 | KDM4E (0.53) | KDM4EALDH1A1MEN1KMT2ATRPV6 | |
| SCHEMBL6132283 | 0.83 | MEN1 (0.55) | KDM4EMEN1KMT2AITGB3ITGA2B | |
| SCHEMBL6134192 | 0.82 | ITGB3 (0.51) | KDM4EMEN1KMT2AITGB3ITGA2B | |
| SCHEMBL6135305 | 0.81 | HRH3 (0.51) | MEN1KMT2AITGB3ITGA2BALOX15 | |
| SCHEMBL6132342 | 0.81 | ALDH1A1 (0.54) | KDM4EALDH1A1MEN1KMT2ATRPV6 | |
| SCHEMBL8763850 | 0.80 | GRIN2B (0.63) | KDM4EALDH1A1KMT2ATRPV6MAPT | |
| SCHEMBL8763848 | 0.80 | GRIN2B (0.63) | KDM4EALDH1A1KMT2ATRPV6MAPT | |
| SCHEMBL3085835 | 0.77 | AOC2 (0.59) | KDM4EALDH1A1MEN1KMT2AITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6884774-B2 | Cyclic hexapeptide derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-04-26 | — | — | US | disclosed |
| US-20030083238-A1 | Cyclic hexapeptide derivatives | ASTELLAS PHARMA INC. (JP) | 2003-05-01 | — | — | US | disclosed |
| EP-1259535-A1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001060846-A1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083238-A1 | Cyclic hexapeptide derivatives | NGLY1, ALG1, CHIT1 | KDM4E 4687/4885ALDH1A1 4718/4885MEN1 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.